Multidisciplinary Care of the Patient with Head and Neck Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 2, 2013, Pages 179-215

  Saloura, Vassiliki ^a   Langerman, Alexander ^a   Rudra, Sonali ^a   Chin, Robert ^a   Cohen, Ezra E W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Altered fractionation; Head and neck cancer; Human papilloma virus; Induction chemotherapy; Multidisciplinary; Robotic surgery; Sequential chemotherapy

Indexed keywords

AFATINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; ZALUTUMUMAB;

ACCELERATED FRACTIONATION; ACNE; ALTERED FRACTIONATION RADIATION; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME DELETION; CONE BEAM COMPUTED TOMOGRAPHY; DERMATITIS; DIARRHEA; DRUG BINDING; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HUMAN; HYPERFRACTIONATION; INFUSION RELATED REACTION; INTENSITY MODULATED RADIATION THERAPY; LASER MICRODISSECTION; LOW DRUG DOSE; METASTASIS; MINIMALLY INVASIVE SURGERY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIDISCIPLINARY CARE; MULTIPLE CYCLE TREATMENT; MYELITIS; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORAL MUCOSITIS; OROPHARYNX CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PLASTIC SURGERY; PROTON THERAPY; PULMONARY ASPIRATION; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK FACTOR; ROBOTICS; SALVAGE THERAPY; SENTINEL LYMPH NODE BIOPSY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURGICAL APPROACH; TEAMWORK; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WART VIRUS; XEROSTOMIA;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC;

EID: 84875514127     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2012.12.001     Document Type: Review

References (142)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Braakhuis B.J., Tabor M.P., Kummer J.A., et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730.
3. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11(1):9-22.
4. Gasco M., Crook T. The p53 network in head and neck cancer. Oral Oncol 2003, 39:222-231.
5. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N Engl J Med 2008, 359(11):1143-1154.
6. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356(19):1944.
7. Gillison M.L., Lowy D.R. A causal role for human papillomavirus in head and neck cancer. Lancet 2004, 363(9420):1488.
8. Sturgis E.M., Cinciripini P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer 2007, 110(7):1429-1435.
9. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011. CA Cancer J Clin 2011, 61(4):212-236.
10. Peretti G., Piazza C., Cocco D., et al. Transoral CO(2) laser treatment for T(is)-T(3) glottic cancer: the University of Brescia experience on 595 patients. Head Neck 2010, 32:977-983.
11. Gallo A., de Vincentis M., Manciocco V., et al. CO2 laser cordectomy for early stage glottic carcinoma: a long-term follow-up of 156 cases. Laryngoscope 2002, 112:370-374.
12. Hartl D.M., de Mones E., Hans S., et al. Treatment of early-stage glottic cancer by transoral laser resection. Ann Otol Rhinol Laryngol 2007, 116:832-836.
13. Smee R.I., Meagher N.S., Williams J.R., et al. Role of radiotherapy in early glottic carcinoma. Head Neck 2010, 32:850-859.
14. Cellai E., Frata P., Magrini S.M., et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys 2005, 63:1378-1386.
15. Chone C.T., Yonehara E., Martins J.E., et al. Importance of anterior commissure involvement in recurrence of early glottic cancer after laser endoscopic resections. Arch Otolaryngol Head Neck Surg 2007, 133:882-887.
16. Stoeckli S.J., Schnieper I., Huguenin P., et al. Early glottic carcinoma: treatment according patient's preference?. Head Neck 2003, 25:1051-1056.
17. Frata P., Cellai E., Magrini S.M., et al. Radical radiotherapy for early glottic cancer: results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys 2005, 63:1387-1394.
18. Grant D.G., Salassa J.R., Hinni M.L., et al. Transoral laser microsurgery for carcinoma of the supraglottic larynx. Otolaryngol Head Neck Surg 2007, 136:900-905.
19. Laccourreye O., Salzer S.J., Brasnu D., et al. Glottic carcinoma with a fixed true vocal cord: outcomes after neoadjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidoepiglottopexy. Otolaryngol Head Neck Surg 1996, 114:400-406.
20. Webster K.T., Samlan R.A., Jones B., et al. Supracricoid partial laryngectomy: swallowing, voice and speech outcomes. Ann Otol Rhinol Laryngol 2010, 119:10-16.
21. Simonelli M., Ruoppolo G., de Vincentis M., et al. Swallowing ability and chronic aspiration after supracricoid partial laryngectomy. Otolaryngol Head Neck Surg 2010, 142:873-878.
22. Haughey B.H., Hinni M.L., Salassa J.R., et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011, 33:1683-1694.
23. Weinstein G.S., O'Malley B.W., Cohen M.A., et al. Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2010, 136:1079-1085.
24. Rusthoven K.E., Raben D., Ballonoff A., et al. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 2008, 118:635-639.
25. Lee N.Y., de Arruda F.F., Puri D.R., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:966-974.
26. Rich J.T., Milov S., Lewis J.S., et al. Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 2009, 119:1709-1719.
27. Cohen M.A., Weinstein G.S., O'Malley B.W., et al. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck 2011, 33:573-580.
28. Steiner W., Fierek O., Ambrosch P., et al. Transoral laser microsurgery of the base of tongue. Arch Otolaryngol Head Neck Surg 2003, 129:36-43.
29. O'Malley B.W., Weinstein G.S., Snyder W., et al. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006, 116:1465-1472.
30. De Almeida J.R., Genden E.M. Robotic surgery for oropharynx cancer: promise, challenges, and future directions. Curr Oncol Rep 2012, 14:148-157.
31. Genden E.M., Kotz T., Tong C.C.L., et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011, 121:1668-1674.
32. White H.N., Moore E.J., Rosenthal E.L., et al. Transoral robotic-assisted surgery for head and neck squamous cell carcinoma: one and 2-year survival analysis. Arch Otolaryngol Head Neck Surg 2010, 136:1248-1252.
33. Moore E.J., Olsen S.M., LaBorde R.R., et al. Long term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc 2012, 87:219-225.
34. Weinstein G.S., Quon H., O'Malley B.W., et al. Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: a subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope 2010, 120:1749-1755.
35. Bocca E. Conservative neck dissection. Laryngoscope 1975, 85:1511-1515.
36. Robbins K.T., Shannon K., Vieira F. Superselective neck dissection after chemoradiation: feasibility based on clinical and pathologic comparisons. Arch Otolaryngol Head Neck Surg 2007, 133:486-489.
37. Langerman A., Plein C., Vokes E.E., et al. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2009, 135:1133-1136.
38. Langerman A., Plein C., Vokes E.E., et al. Neck dissection planning based on post-chemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009, 135:876-880.
39. Ferlito A., Corry J., Silver C.E., et al. Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck 2010, 32:253-261.
40. de Bree R., van den Putten L., Brouwer J., et al. Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 2009, 45:386-393.
41. Nieuwenhuis E.J., Castelijns J.A., Pijpers R., et al. Wait-and-see policy for the N0 neck in early stage oral and oropharyngeal squamous cell carcinoma using ultrasound-guided cytology: is there a role for identification of the sentinel node?. Head Neck 2002, 24:282-289.
42. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
43. Murer K., Huber G.F., Haile S.R., et al. Comparison of morbidity between sentinel node biopsy and elective neck dissection for treatment of the N0 neck in patients with oral squamous cell carcinoma. Head Neck 2011, 33:1260-1264.
44. Civantos F.J., Zitsch R.P., Schuller D.E., et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol 2010, 28:1395-1400.
45. Alkureishi L.W., Ross G.L., Shoaib T., et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of European multicenter trial. Ann Surg Oncol 2010, 17:2459-2464.
46. Flach G.B., Broglie M.A., van Schie A., et al. Sentinel node biopsy for oral and oropharyngeal squamous cell carcinoma in the previously treated neck. Oral Oncol 2012, 48:85-89.
47. Kim A.J., Suh J.D., Sercarz J.A., et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007, 117:1019-1023.
48. Goodwin W.J. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?. Laryngoscope 2000, 110:1-18.
49. Hutcheson K.A., Alvarez C.P., Barringer D.A., et al. Outcomes of elective total laryngectomy for laryngopharyngeal dysfunction in disease-free head and neck cancer survivors. Otolaryngol Head Neck Surg 2012, 146:585-590.
50. Starmer H.M., Agrawal N., Koch W., et al. Does prosthesis diameter matter? The relationship between voice prosthesis diameter and complications. Otolaryngol Head Neck Surg 2011, 144:740-746.
51. Spiegel J.H., Polat J.K. Microvascular flap reconstruction by otolaryngologists: prevalence, postoperative care, and monitoring techniques. Laryngoscope 2007, 117:485-490.
52. Lutz B.S., Wei F.C. Microsurgical workhorse flaps in head and neck reconstruction. Clin Plast Surg 2005, 32:421-430.
53. Park C.W., Miles B.A. The expanding role of the anterolateral thigh free flap in head and neck reconstruction. Curr Opin Otolaryngol Head Neck Surg 2011, 19:263-268.
54. Kruse A.L., Bredell M.G., Lubbers H.T., et al. Clinical reliability of radial forearm free-flap procedure in reconstructive head and neck surgery. J Craniofac Surg 2011, 22:822-825.
55. Dean N.R., Wax M.K., Virgin F.W., et al. Free flap reconstruction of lateral mandibular defects: indications and outcomes. Otolaryngol Head Neck Surg 2012, 146:547-552.
56. Moukarbel R.V., White J.B., Fung K., et al. The scapular free flap: when versatility is needed in head and neck reconstruction. J Otolaryngol Head Neck Surg 2010, 39:572-578.
57. Genden E.M., Rinaldo A., Suarez C., et al. Complications of free flap transfers for head and neck reconstruction following cancer resection. Oral Oncol 2004, 40:979-984.
58. Arce K., Bell R.B., Potter J.K., et al. Vascularized free tissue transfer for reconstruction of ablative defects in oral and oropharyngeal cancer patients undergoing salvage surgery following concomitant chemoradiation. Int J Oral Maxillofac Surg 2012, 41:733-738.
59. Choi S., Schwartz D.L., Farwell D.G., et al. Radiation therapy does not impact local complications rates after free flap reconstruction for head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:1308-1312.
60. Pfister D.G., Ang K.K., Brizel D., National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, et al. Head and neck cancers. J Natl Compr Canc Netw 2011, 9(6):596-650.
61. Ang K.K., Trotti A., Brown B.W., et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 51(3):571-578.
62. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27(10):843-850.
63. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350(19):1945-1952.
64. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25(4):231-241.
65. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48(1):7-16.
66. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997, 44(2):111-121.
67. Saunders M.I., Rojas A.M., Parmar M.K., et al. Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010, 77(1):3-8.
68. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44(2):123-136.
69. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362(9388):933-940.
70. Ang K.K., Wheeler R.H., Rosenthal D.I., et al. A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of efficacy and toxicity. Int J Radiat Oncol Biol Phys 2010, 77(1):1-2.
71. Yamazaki H., Nishiyama K., Tanaka E., et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006, 64(1):77-82.
72. Le Q.T., Fu K.K., Kroll S., et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997, 39(1):115-126.
73. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350(19):1937-1944.
74. O'Sullivan B., Warde P., Grice B., et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 2001, 51(2):332-343.
75. Mendenhall W.M., Morris C.G., Amdur R.J., et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol 2006, 29(3):290-297.
76. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25(31):4873-4879.
77. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66(4):981-991.
78. Nutting C., A'Hern R., Rogers M.S., et al. First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J Clin Oncol 2009, 27(suppl):18s. [abstract LBA6006].
79. Parvathaneni U., Laramore G.E., Liao J.J. Technical advances and pitfalls in head and neck radiotherapy. J Oncol 2012, 2012:597467.
80. Mendenhall N.P., Malyapa R.S., Su Z., et al. Proton therapy for head and neck cancer: rationale, potential indications, practical considerations, and current clinical evidence. Acta Oncol 2011, 50(6):763-771.
81. Simone C.B., Ly D., Dan T.D., et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol 2011, 101(3):376-382.
82. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991, 324(24):1685-1690. [No authors listed].
83. Lefebvre J.L., Andry G., Chevalier D., et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012, 23(10):2708-2714.
84. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349(22):2091-2098.
85. Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement). 2006. p. 5517.
86. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
87. Agarwala S.S., Cano E., Heron D.E., et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 2007, 18(7):1224-1229.
88. Vermorken J.B., Remenar E., van Herpen C., EORTC 24971/TAX 323 Study Group, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357(17):1695-1704.
89. Posner M.R., Hershock D.M., Blajman C.R., TAX 324 Study Group, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357(17):1705-1715.
90. Cohen E.E., Karrison T., Kocherginsky M., et al. DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2012 ASCO Annual Meeting. J Clin Oncol 2012, 30(suppl). [abstract 5500].
91. Salama J.K., Stenson K.M., Kistner E.O., et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008, 19(10):1787-1794.
92. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010, 28(1):8-14.
93. Pignon J.P., le Maître A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92(1):4-14.
94. Chougule P.B., Akhtar M.S., Akerley W., et al. Chemoradiotherapy for advanced inoperable head and neck cancer: a phase II study. Semin Radiat Oncol 1999, 9:58-63.
95. Argiris A., Haraf D.J., Kies M.S., et al. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist 2003, 8:350-360.
96. Vokes E.E., Panje W.R., Schilsky R.L., et al. Hydroxyurea, fluorouracil and concomitant radiotherapy in poor prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989, 7:761-768.
97. Byfield J.E., Sharp T.R., Frankel S.S., et al. Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 1984, 2(5):406-413.
98. Taylor S.G., Murthy A.K., Showel J.L., et al. Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy. Cancer Treat Rep 1985, 69(9):933-939.
99. Haraf D.J., Kies M., Rademaker A.W., et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol 1999, 17:638-644.
100. Garden AS, Pajak TF, Vokes E et al. Preliminary results of RTOG 9703- a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. 2001 ASCO Annual Meeting. Proc Am Soc Clin Oncol 2001:20. [abstract 891].
101. Haraf D.J., Vokes E.E., Weichselbaum R.R., et al. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor prognosis head and neck cancer. Laryngoscope 1992, 102:630-636.
102. Vokes E.E., Haraf D.J., Brockstein B.E., et al. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol 1999, 9(2 Suppl 1):70-76.
103. Ang K.K., Zhang Q.E., Rosenthal D.I., et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011, 29(suppl). [abstract 5500].
104. Posner M.R., Haddad R.I., Wirth L., et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004, 31:778-785.
105. Rooney M., Kish J., Jacobs J., et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985, 55:1123-1128.
106. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. Lancet 2000, 355:949-955.
107. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127.
108. Colevas A.D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24(17):2644-2652.
109. Urba S.G., Forastiere A.A. Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology (Williston Park) 1989, 3(4):79-88. [discussion: 88, 90, 97-8].
110. Jacobs C., Lyman G., Velez-Garcia E., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992, 10:257-263.
111. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992, 10(8):1245-1251.
112. Gibson M.K., Li Y., Murphy B., et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23:3562-3567.
113. Ferrari D., Fiore J., Codecà C., et al. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs 2009, 20(3):185-190.
114. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25(16):2171-2177.
115. Hitt R., Irigoyen A., Cortes-Funes H., et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Spanish Head and Neck Cancer Cooperative Group (TTCC). Ann Oncol 2012, 23(4):1016-1022.
116. Licitra L., Mesia R., Rivera F., et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011, 22(5):1078-1087.
117. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 53(5):1192-1202.
118. Jun H.J., Ahn M.J., Kim H.S., et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008, 99(1):167-172.
119. Chung C.H., Parker J.S., Karaca G., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5:489-500.
120. Mellin Dahlstrand H., Lindquist D., Bjornestal L., et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005, 25(6C):4375-4383.
121. Lindel K., Beer K.T., Laissue J., et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001, 92(4):805-813.
122. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363(1):24-35.
123. Westra W.H., Taube J.M., Poeta M.L., et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008, 14:366-369.
124. Tong C.C., Kao J., Sikora A.G., et al. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 2012, 54(1-3):266-274.
125. Ferris R.L., Hunt J.L., Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005, 33(2):113-133.
126. De Costa A.M., Young M.R. Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs 2011, 22(7):674-681.
127. Lyford-Pike S., Peng S., Taube J.M., et al. PD-1:PD-L1(B7-H1) pathway in adaptive resistance: a novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. Oral Abstract Session, Head and Neck Cancer. J Clin Oncol 2012, 30(suppl). [abstract 5506].
128. Argiris A., Brockstein B.E., Haraf D.J., et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 2004, 10(6):1956-1962.
129. Vermorken J.B., Stöhlmacher J., Davidenko I., et al. An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM). J Clin Oncol 2009, 27(Suppl 15):313s. [abstract 6050].
130. Machiels J.P., Subramanian S., Ruzsa A., et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011, 12(4):333-343.
131. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22(1):77-85.
132. Stewart J.S., Cohen E.E., Licitra L. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009, 27(11):1864-1871.
133. Seiwert T.Y., Clement P.M., Cupissol D., et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study. J Clin Oncol 2010, 28. [abstract 5501].
134. de Souza J.A., Davis D.W., Zhang Y. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2012, 18(8):2336-2343.
135. Le Tourneau C., Winquist E., Hottes S.J., et al. Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2010, 28:15s. [Suppl; abstract 5531].
136. Gibson M.K., Kies M., Kim S., et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. J Clin Oncol 2009, 27:15s. [Suppl; abstract 6049].
137. Cohen E.E., Davis D.W., Karrison T.G., et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009, 10(3):247-257.
138. Argiris A., Karamouzis M.V., Gooding W.E., et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011, 29(9):1140-1145.
139. Machiels J.P., Henry S., Zanetta S., et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010, 28(1):21-28.
140. Choong N.W., Kozloff M., Taber D., et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010, 28(5):677-683.
141. Elser C., Siu L.L., Winquist E., et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007, 25(24):3766-3773.
142. Williamson S.K., Moon J., Huang C.H., et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010, 28(20):3330-3335.